Search

Justin K Belardi

from Pittsburgh, PA
Age ~42
Get Report
Also known as:
Justin R Belardi
Phone and address:
1176 Windmill Ln, Pittsburgh, PA 15237
Related to:
Beverly A Creagh, 63Alison M Lescisin, 48
Connected to:
Daniel C Belardinelli, 52Jennifer Belardi, 42Therese A Belardi, 74Daniel S Belardo, 37Danilo G Belardo, 73Geraldine L Belardo, 71Ian X Belardo, 51Joe N Belardo, 59Linda M Belardo, 57Michael D Belardo, 46

Justin Belardi Phones & Addresses

  • 1176 Windmill Ln, Pittsburgh, PA 15237
  • Penllyn, PA
  • 564 Prospect St #A5, New Haven, CT 06511
  • 644 Orange St, New Haven, CT 06511
  • 644 Orange St #1B, New Haven, CT 06511
  • 2066 Carriage Hill Rd, Allison Park, PA 15101

Work

Company: Knopp biosciences llc Jan 1, 2012 Position: Senior research investigator

Education

School / High School: Yale University

Skills

Chromatography • Organic Chemistry • Biochemistry • Drug Design • Drug Development • Synthetic Organic • Chemistry • Hplc • Organic Synthesis • Nmr • Neuroscience • Medicinal Chemistry • Drug Discovery

Resumes

Resumes

Justin Belardi Photo 1

Senior Research Investigator

View page
Location:
Pittsburgh, PA
Work:
Knopp Biosciences Llc
Senior Research Investigator
Merck Jun 1, 2009 - Jan 1, 2012
Senior Research Chemist
Education:
Yale University
Villanova University
Skills:
Chromatography
Organic Chemistry
Biochemistry
Drug Design
Drug Development
Synthetic Organic
Chemistry
Hplc
Organic Synthesis
Nmr
Neuroscience
Medicinal Chemistry
Drug Discovery

Publications

Us Patents

Piperidinone Carboxamide Spirohydantoin Cgrp Receptor Antagonists

View page
US Patent:
20140011827, Jan 9, 2014
Filed:
Mar 14, 2012
Appl. No.:
14/005673
Inventors:
Ian M. Bell - Harlysville PA, US
Justin Belardi - West Point PA, US
International Classification:
C07D 487/10
US Classification:
514278, 546 15
Abstract:
The present invention is directed to piperidinone carboxamide spirohydantoin derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Kv7 Channel Activators Compositions And Methods Of Use

View page
US Patent:
20230000831, Jan 5, 2023
Filed:
Jan 7, 2022
Appl. No.:
17/570536
Inventors:
- Pittsburgh PA, US
Scott S. HARRIED - Sun Prairie WI, US
Lynn RESNICK - Pittsburgh PA, US
George T. TOPALOV - Pittsburgh PA, US
Justin K. BELARDI - Pittsburgh PA, US
Charles A. FLENTGE - Mars PA, US
David A. MARESKA - Pittsburgh PA, US
James S. HALE - Pittsburgh PA, US
International Classification:
A61K 31/4184
Abstract:
Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.

Kv7 Channel Activators Compositions And Methods Of Use

View page
US Patent:
20210130299, May 6, 2021
Filed:
Oct 22, 2020
Appl. No.:
17/077068
Inventors:
- Pittsburgh PA, US
Scott S. HARRIED - Sun Prairie WI, US
Lynn RESNICK - Pittsburgh PA, US
George T. TOPALOV - Pittsburgh PA, US
Justin K. BELARDI - Pittsburgh PA, US
Charles A. FLENTGE - Mars PA, US
David A. MARESKA - McMurray PA, US
James S. HALE - Pittsburgh PA, US
International Classification:
C07D 235/30
C07D 471/04
C07D 405/04
Abstract:
Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.

Benzoimidazol-1,2-Yl Amides As Kv7 Channel Activators

View page
US Patent:
20200062714, Feb 27, 2020
Filed:
Oct 31, 2017
Appl. No.:
16/346292
Inventors:
- Pittsburgh PA, US
George T. TOPALOV - Pittsburgh PA, US
Justin K. BELARDI - Pittsburgh PA, US
Charles A. FLENTGE - Mars PA, US
James S. HALE - Pittsburgh PA, US
David A. MARESKA - McMurray PA, US
International Classification:
C07D 235/30
C07D 405/04
C07D 403/04
C07D 413/04
C07D 401/12
Abstract:
Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.

Benzoimidazol-1,2-Yl Amides As Kv7 Channel Activators

View page
US Patent:
20200002292, Jan 2, 2020
Filed:
Jul 2, 2019
Appl. No.:
16/460449
Inventors:
- Pittsburgh PA, US
George T. TOPALOV - Pittsburgh PA, US
Justin K. BELARDI - Pittsburgh PA, US
James S. HALE - Pittsburgh PA, US
Scott S. HARRIED - Pittsburgh PA, US
Charles A. FLENTGE - Mars PA, US
David A. MARESKA - McMurray PA, US
International Classification:
C07D 235/30
C07D 401/04
C07D 413/04
C07D 403/04
C07D 405/12
C07D 401/12
Abstract:
Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.

Kv7 Channel Activators Compositions And Methods Of Use

View page
US Patent:
20190284142, Sep 19, 2019
Filed:
Mar 19, 2019
Appl. No.:
16/358642
Inventors:
- Pittsburgh PA, US
Scott S. HARRIED - Sun Prairie WI, US
Lynn RESNICK - Pittsburgh PA, US
George T. TOPALOV - Pittsburgh PA, US
Justin K. BELARDI - Pittsburgh PA, US
Charles A. FLENTGE - Mars PA, US
David A. MARESKA - McMurray PA, US
James S. HALE - Pittsburgh PA, US
International Classification:
C07D 235/30
C07D 405/04
C07D 471/04
Abstract:
Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.

Imidazo[4,5-B]Pyridin-2-Yl Amides As Kv7 Channel Activators

View page
US Patent:
20190002464, Jan 3, 2019
Filed:
Sep 7, 2018
Appl. No.:
16/124853
Inventors:
- Pittsburgh PA, US
George T. TOPALOV - Pittsburgh PA, US
Charles A. FLENTGE - Mars PA, US
James S. HALE - Pittsburgh PA, US
David A. MARESKA - McMurray PA, US
Justin K. BELARDI - Pittsburgh PA, US
Kai ZHANG - Wexford PA, US
Scott S. HARRIED - Sun Prairie WI, US
International Classification:
C07D 471/04
C07D 519/00
Abstract:
Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.

Benzoimidazol-1,2-Yl Amides As Kv7 Channel Activators

View page
US Patent:
20180148419, May 31, 2018
Filed:
Jan 25, 2018
Appl. No.:
15/879792
Inventors:
- Pittsburgh PA, US
George T. TOPALOV - Pittsburgh PA, US
Justin K. BELARDI - Pittsburgh PA, US
James S. HALE - Pittsburgh PA, US
Scott S. HARRIED - Pittsburgh PA, US
Charles A. FLENTGE - Mars PA, US
David A. MARESKA - McMurray PA, US
International Classification:
C07D 235/30
C07D 401/12
C07D 403/04
C07D 405/12
C07D 413/04
C07D 401/04
Abstract:
Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
Control profile
Justin K Belardi from Pittsburgh, PA, age ~42 Get Report